Difference between revisions of "HCG11"
| Line 4: | Line 4: | ||
===Synonyms=== | ===Synonyms=== | ||
"bK14H9.3, FLJ14049, FLJ30357" | "bK14H9.3, FLJ14049, FLJ30357" | ||
| + | [[File:lncRNA HCG11 was downregulated in prostate cancer.jpg|right|thumb|400px|'''lncRNA HCG11 was downregulated in prostate cancer. '''<ref name="ref1" />]] | ||
| + | [[File:GO and KEGG pathway analysis of HCG11.jpg|right|thumb|400px|'''GO and KEGG pathway analysis of HCG11. '''<ref name="ref1" />]] | ||
===Chromosome=== | ===Chromosome=== | ||
6p22.2 | 6p22.2 | ||
===RefSeq ID=== | ===RefSeq ID=== | ||
NR_026790 | NR_026790 | ||
| − | |||
| − | |||
===Disease=== | ===Disease=== | ||
prostate cancer | prostate cancer | ||
| − | |||
| − | |||
| − | |||
===Expression=== | ===Expression=== | ||
| − | |||
| − | |||
{| class='wikitable' style="text-align:center" | {| class='wikitable' style="text-align:center" | ||
|- | |- | ||
| Line 31: | Line 26: | ||
===Function=== | ===Function=== | ||
Downregulation of HCG11 predicts a poor prognosis in prostate cancer. <ref name="ref1" /> | Downregulation of HCG11 predicts a poor prognosis in prostate cancer. <ref name="ref1" /> | ||
| + | HCG11 has the ability in the regulation of signal transduction, transcription, cell adhesion, and development.<ref name="ref1" /> | ||
| + | ==Labs working on this lncRNA== | ||
| + | * State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai, 200433, People's Republic of China.<ref name="ref1" /> | ||
| + | * Center of Translational Medicine, Central Hospital of Zibo, Zibo, 255036, People's Republic of China.<ref name="ref1" /> | ||
| + | * Center of Translational Medicine, Central Hospital of Zibo, Zibo, 255036, People's Republic of China. <ref name="ref1" /> | ||
| + | * State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai, 200433, People's Republic of China.<ref name="ref1" /> | ||
| + | ==References== | ||
| + | <references> | ||
| + | <ref name="ref1"> Zhang, Y., et al., Downregulation of long non-coding RNA HCG11 predicts a poor prognosis in prostate cancer. Biomed Pharmacother, 2016. 83: p. 936-941. | ||
| + | </ref>(1) | ||
| + | </references> | ||
Latest revision as of 15:46, 27 October 2017
Contents
Annotated Information
Approved Symbol
HCG11 (HLA complex group 11 (non-protein coding))
Synonyms
"bK14H9.3, FLJ14049, FLJ30357"
lncRNA HCG11 was downregulated in prostate cancer. [1]
GO and KEGG pathway analysis of HCG11. [1]
Chromosome
6p22.2
RefSeq ID
NR_026790
Disease
prostate cancer
Expression
| Experiment | Forward primer | Reverse primer |
|---|---|---|
| qPCR | 5′-AGGAGTGGTTGCATTTGGGA-3′ | 5′-CCCACCACGCAGTGAATAGT-3′[1] |
HCG11 is significantly higher in ovary,breast,thyroid and prostate. TCGA analysis reveals that the expression of HCG11 is significantly suppressed in prostate cancers compared with adjacent normal tissues [1]
Function
Downregulation of HCG11 predicts a poor prognosis in prostate cancer. [1] HCG11 has the ability in the regulation of signal transduction, transcription, cell adhesion, and development.[1]
Labs working on this lncRNA
- State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai, 200433, People's Republic of China.[1]
- Center of Translational Medicine, Central Hospital of Zibo, Zibo, 255036, People's Republic of China.[1]
- Center of Translational Medicine, Central Hospital of Zibo, Zibo, 255036, People's Republic of China. [1]
- State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai, 200433, People's Republic of China.[1]
